Premium
Effects of FBCx® on lipid lowering in LDLr‐KO mice
Author(s) -
Wagner Elke,
Jen KL. Catherine,
Artiss Joseph,
Remaley Alan T
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a341-d
Subject(s) - medicine , endocrinology , ldl receptor , triglyceride , blood lipids , chemistry , cholesterol , hyperlipidemia , receptor , lipoprotein , diabetes mellitus
FBCx®, a new soluble fiber (α‐cyclodextrin), has been shown to bind with fat, thus reducing the absorption of dietary fat. It also reduces blood lipid levels and prevents body weight gain in high‐fat fed rats. In order to investigate the efficacy of FBCx in reducing the blood cholesterol (C) levels and possibly atherogenic lesion development in a common mouse model of atherosclerosis, female LDLr knock‐out (LDLr‐KO) mice, 10 wks old, were divided into the high‐fat “western” diet (CON, 21.2% milkfat w/w, n =10) or the same diet with 2.12% FBCx (FBCx, n =10) groups. After 10 wks ad‐lib feeding, mice were fasted for 6 h and blood samples collected by retro‐orbital bleeding. Food intake and body weight were the same in the 2 groups. Compared to CON mice, mice fed the FBCx diet showed significant reductions in blood total C (−14%, 30.5±3.7 vs. 26.2±3.7 mmol/l, p<.05); phospholipids (−11%, 16.3±1.8 vs. 14.4±1.8 mmol/l, p<.05); free C (−15.9%, 9.0±1.1 vs. 7.6±1.4 mmol/l, p<.05) and C ester (−13.3%, 21.5±2.5 vs. 18.7±2.5 mmol/l, p<.05). Fasting triglyceride levels were not different between the 2 groups. FPLC data showed that the reduction in C levels was mainly in the LDL containing fractions. Therefore, in an animal model of hypercholesterolemia due to the lack of the LDL‐receptor, FBCx demonstrated its efficacy in reducing the blood cholesterol and its components. Oral FBCx may be an effective treatment for hypercholesterolemia.